Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
University of North Carolina, Chapel Hill
New York University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01589094
First received: April 27, 2012
Last updated: May 4, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)